These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 27510890

  • 1. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
    Miners AH, Krishnan S, Pasi KJ.
    J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
    [Abstract] [Full Text] [Related]

  • 2. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [Abstract] [Full Text] [Related]

  • 3. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML, Desai V, Maro GS, Yan S.
    J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
    [Abstract] [Full Text] [Related]

  • 4. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N, Jovanović J, Schlueter M, Kritikou P, Wilson K, Myrén KJ.
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [Abstract] [Full Text] [Related]

  • 5. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
    Iorio A, Krishnan S, Myrén KJ, Lethagen S, McCormick N, Yermakov S, Karner P.
    Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
    [Abstract] [Full Text] [Related]

  • 6. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G.
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [Abstract] [Full Text] [Related]

  • 7. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
    Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF.
    Blood; 2012 Mar 29; 119(13):3031-7. PubMed ID: 22223821
    [Abstract] [Full Text] [Related]

  • 8. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S, Maro GS, Desai V, Simpson ML.
    J Manag Care Spec Pharm; 2020 Oct 29; 26(10):1258-1265. PubMed ID: 32820685
    [Abstract] [Full Text] [Related]

  • 9. The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein.
    Leksa NC, Chiu PL, Bou-Assaf GM, Quan C, Liu Z, Goodman AB, Chambers MG, Tsutakawa SE, Hammel M, Peters RT, Walz T, Kulman JD.
    J Thromb Haemost; 2017 Jun 29; 15(6):1167-1179. PubMed ID: 28397397
    [Abstract] [Full Text] [Related]

  • 10. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E, Negrier C, Gozzi P, Blaas PM, Lethagen S.
    Haemophilia; 2016 May 29; 22(3):389-96. PubMed ID: 26863900
    [Abstract] [Full Text] [Related]

  • 11. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States.
    McMullen S, Buckley B, Hall E, Kendter J, Johnston K.
    Value Health; 2017 Jan 29; 20(1):93-99. PubMed ID: 28212975
    [Abstract] [Full Text] [Related]

  • 12. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
    Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF, A-LONG Investigators.
    Blood; 2014 Jan 16; 123(3):317-25. PubMed ID: 24227821
    [Abstract] [Full Text] [Related]

  • 13. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S, Núñez R, Poveda JL, Kurnik K, Goldmann G, Andreozzi V, Vandewalle B, Santos S.
    Adv Ther; 2021 Sep 16; 38(9):4872-4884. PubMed ID: 34368918
    [Abstract] [Full Text] [Related]

  • 14. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
    Olivieri M, Simpson M, Yan S, Fedorovsky J, Zhang X, Tomic R, Pinachyan K, Mancuso ME.
    Curr Med Res Opin; 2022 Jul 16; 38(7):1133-1139. PubMed ID: 35387548
    [Abstract] [Full Text] [Related]

  • 15. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
    Nestorov I, Neelakantan S, Ludden TM, Li S, Jiang H, Rogge M.
    Clin Pharmacol Drug Dev; 2015 Jul 16; 4(3):163-74. PubMed ID: 27140796
    [Abstract] [Full Text] [Related]

  • 16. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE.
    Drugs; 2021 Nov 16; 81(17):2035-2046. PubMed ID: 34743314
    [Abstract] [Full Text] [Related]

  • 17. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
    Lorenzoni V, Triulzi I, Turchetti G.
    BMC Health Serv Res; 2018 Aug 02; 18(1):596. PubMed ID: 30071878
    [Abstract] [Full Text] [Related]

  • 18. Recombinant factor VIII Fc for the treatment of haemophilia A.
    Hermans C, Mancuso ME, Nolan B, Pasi KJ.
    Eur J Haematol; 2021 Jun 02; 106(6):745-761. PubMed ID: 33650192
    [Abstract] [Full Text] [Related]

  • 19. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, Drager D, Moore N, Liu J, Holthaus AM, Sommer JM, Ismail A, Rabinovich D, Liu Z, van der Flier A, Goodman A, Furcht C, Tie M, Carlage T, Mauldin R, Dobrowsky TM, Liu Z, Mercury O, Zhu L, Mei B, Schellenberger V, Jiang H, Pierce GF, Salas J, Peters R.
    Blood; 2020 Apr 23; 135(17):1484-1496. PubMed ID: 32078672
    [Abstract] [Full Text] [Related]

  • 20. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
    Gringeri A, Wolfsegger M, Steinitz KN, Reininger AJ.
    Haemophilia; 2015 May 23; 21(3):300-306. PubMed ID: 25643824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.